S20928

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 532613

CAS#: 152302-33-5

Description: S20928 is a melatonin receptor antagonist.


Price and Availability

Size
Price

Size
Price

Size
Price

S20928 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 532613
Name: S20928
CAS#: 152302-33-5
Chemical Formula: C17H19NO
Exact Mass: 253.1467
Molecular Weight: 253.35
Elemental Analysis: C, 80.60; H, 7.56; N, 5.53; O, 6.32


Synonym: S20928; S 20928; S-20928.

IUPAC/Chemical Name: N-(2-naphthalen-1-ylethyl)cyclobutanecarboxamide

InChi Key: GLXSBZGTGMPDKH-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H19NO/c19-17(15-8-4-9-15)18-12-11-14-7-3-6-13-5-1-2-10-16(13)14/h1-3,5-7,10,15H,4,8-9,11-12H2,(H,18,19)

SMILES Code: O=C(C1CCC1)NCCC2=C3C=CC=CC3=CC=C2


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Mao L, Dauchy RT, Blask DE, Dauchy EM, Slakey LM, Brimer S, Yuan L, Xiang S, Hauch A, Smith K, Frasch T, Belancio VP, Wren MA, Hill SM. Melatonin suppression of aerobic glycolysis (Warburg effect), survival signalling and metastasis in human leiomyosarcoma. J Pineal Res. 2016 Mar;60(2):167-77. doi: 10.1111/jpi.12298. Epub 2015 Dec 23. PubMed PMID: 26607298.

2: Dauchy RT, Blask DE, Dauchy EM, Davidson LK, Tirrell PC, Greene MW, Tirrell RP, Hill CR, Sauer LA. Antineoplastic effects of melatonin on a rare malignancy of mesenchymal origin: melatonin receptor-mediated inhibition of signal transduction, linoleic acid metabolism and growth in tissue-isolated human leiomyosarcoma xenografts. J Pineal Res. 2009 Aug;47(1):32-42. doi: 10.1111/j.1600-079X.2009.00686.x. Epub 2009 May 27. PubMed PMID: 19486272.

3: Sanchez-Hidalgo M, Lu Z, Tan DX, Maldonado MD, Reiter RJ, Gregerman RI. Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS17/2.8 cells: implications for osteoblast differentiation and osteoporosis. Am J Physiol Regul Integr Comp Physiol. 2007 Jun;292(6):R2208-15. Epub 2007 Mar 22. PubMed PMID: 17379847.

4: Blask DE, Dauchy RT, Sauer LA, Krause JA. Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis. 2004 Jun;25(6):951-60. Epub 2004 Jan 30. PubMed PMID: 14754876.